Management of Stage I–II Testicular Germ Cell Tumours: Current Treatment Paradigm and Future Perspectives
Canadian Oncology Today · 2025
DOI: 10.58931/cot.2025.2238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Oncology Today, 2025. Verfasst von Deepro Chowdhury und 3 weiteren Autor:innen. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Testicular cancer is the most common solid tumour in males aged 15–44 years, with an estimated 1,300 new cases in Canada in 2024. Over 90% are germ cell tumours (GCTs) originating from spermatocyte precursors, with most arising in the testes. Risk factors include cryptorchidism, gonadal dysgenesis, genetic syndromes such as Klinefelter syndrome, family history, and possibly cannabis use. This review summarizes the evidence‑based diagnosis and management strategies of clinical stage I (CSI) and II (CSII) testicular GCTs used at the Princess Margaret Cancer Centre (PM), highlighting potential clinical pitfalls and future directions.
Zitieren
APA
Chowdhury, D., Glicksman, R., Hamilton, R. J., & Jiang, D. M. (2025). Management of Stage I–II Testicular Germ Cell Tumours: Current Treatment Paradigm and Future Perspectives. Canadian Oncology Today. https://doi.org/10.58931/cot.2025.2238
Vancouver
Chowdhury D, Glicksman R, Hamilton RJ, Jiang DM. Management of Stage I–II Testicular Germ Cell Tumours: Current Treatment Paradigm and Future Perspectives. Canadian Oncology Today. 2025. doi:10.58931/cot.2025.2238
BibTeX
@article{Chowdhury2025,
author = {Chowdhury, Deepro and Glicksman, Rachel and Hamilton, Robert J. and Jiang, Di Maria},
title = {Management of Stage I–II Testicular Germ Cell Tumours: Current Treatment Paradigm and Future Perspectives},
journal = {Canadian Oncology Today},
year = {2025},
doi = {10.58931/cot.2025.2238}
}
EUVIMED